Temat: "CTLA-4" - OpacWWW - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Detection of CTLA-4 level and humeral immune response after the second dose of COVID-19 vaccine in certain Iraqi provinces participants.
Autorzy:: Al-Kaif LAIK; Department of Medical Microbiology, Hammurabi College of Medicine, University of Babylon, Hillah, Babylon, Iraq.; Department of Medical Laboratory Techniques, Al-Mustaqbal University, Hillah, Babylon, Iraq.
Al-Ameri H; Department of Medical Laboratory Techniques, Al-Mustaqbal University, Hillah, Babylon, Iraq.
Alfatlawi WRO; Department of Microbiology, College of Medicine, Babylon University, Hillah, Babylon, Iraq.
Mahdi AE; Basic Science Department, College of Dentistry, University of Babylon, Hillah, Babylon, Iraq.
Al-Khafaji YAK; Department of Anesthesia Techniques, Al-Mustaqbal University, Hillah, Babylon, Iraq.
Al-Saadi MA; Basic Science Department, College of Dentistry, University of Babylon, Hillah, Babylon, Iraq.
Al-Charrakh AH; Basic Science Department, College of Dentistry, University of Babylon, Hillah, Babylon, Iraq.
Al-Mammori RT; Babylon GIT Diseases Center, Merjan Medical City, Babylon Province, Hilla, Iraq.
Akkaif MA; Department of Cardiology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Jan 05; Vol. 19 (1), pp. e0296521. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19 Vaccines*
Immunity, Humoral*
Humans ; Antibodies, Viral ; CTLA-4 Antigen ; Immunity ; Immunoglobulin G ; Iraq/epidemiology ; SARS-CoV-2

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Autorzy:: Khunger A; Department of Internal Medicine, Memorial Hospital West, Pembroke Pines, Florida, United States of America.
Piazza E; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Warren S; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Smith TH; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Ren X; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
White A; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Elliott N; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Cesano A; ESSA Pharma, South San Francisco, California, United States of America.
Beechem JM; NanoString® Technologies, Inc., Seattle, Washington, United States of America.
Kirkwood JM; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States of America.
Tarhini AA; Department of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Jan 11; Vol. 16 (1), pp. e0245287. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2021).
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Transcription, Genetic*/drug effects
CTLA-4 Antigen/*antagonists & inhibitors
Inflammation/*genetics
Interferon-alpha/*therapeutic use
Melanoma/*immunology
Melanoma/*pathology
Skin Neoplasms/*immunology
Skin Neoplasms/*pathology
CTLA-4 Antigen/metabolism ; Combined Modality Therapy ; Disease-Free Survival ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/drug effects ; Immunotherapy ; Interferon-alpha/pharmacology ; Ipilimumab/therapeutic use ; Melanoma/drug therapy ; Melanoma/genetics ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Survival Analysis ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.
Autorzy:: Siewe N; School of Mathematical Sciences, College of Science, Rochester Institute of Technology, Rochester, New York, United States of America.
Friedman A; Department of Mathematics, The Ohio State University, Columbus, Ohio, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2022 Nov 10; Vol. 17 (11), pp. e0277248. Date of Electronic Publication: 2022 Nov 10 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Melanoma*
Neoplasms, Second Primary*/drug therapy
Humans ; CTLA-4 Antigen ; Ipilimumab/therapeutic use ; Immune Checkpoint Inhibitors ; Immunotherapy/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Steroids/therapeutic use ; Models, Theoretical

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Autorzy:: Iwata TN; Oncology Research Laboratories I, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Sugihara K; Oncology Research Laboratories I, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Wada T; Oncology Research Laboratories I, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Agatsuma T; Oncology Research Laboratories I, R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Oct 01; Vol. 14 (10), pp. e0222280. Date of Electronic Publication: 2019 Oct 01 (Print Publication: 2019).
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Monoclonal, Humanized/*pharmacology
Breast Neoplasms/*drug therapy
CTLA-4 Antigen/*immunology
Camptothecin/*analogs & derivatives
Immunity, Innate/*drug effects
Immunoconjugates/*pharmacology
Animals ; Antibodies/drug effects ; Antibodies/immunology ; Breast Neoplasms/genetics ; Breast Neoplasms/immunology ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; Camptothecin/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Disease Models, Animal ; Female ; Humans ; Mice ; Receptor, ErbB-2/genetics ; Trastuzumab

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis.
Autorzy:: Moiseev I; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Tcvetkov N; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Epifanovskaya O; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Babenko E; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Parfenenkova A; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Bakin E; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Yurovskaya K; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.
Morozova E; RM Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russian Federation.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2022 Oct 25; Vol. 17 (10), pp. e0275399. Date of Electronic Publication: 2022 Oct 25 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Hepatitis A Virus Cellular Receptor 2*
Myelodysplastic Syndromes*/metabolism
Humans ; CTLA-4 Antigen ; Prospective Studies ; Programmed Cell Death 1 Receptor/genetics ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
Autorzy:: Xu J; Department of General Surgery, Shijiazhuang People's Hospital, Shijiazhuang, P. R. China.; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P. R. China.; Hebei Medical University, Shijiazhuang, P. R. China.
Ma H; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P. R. China.; Hebei Medical University, Shijiazhuang, P. R. China.
Shan B; Hebei Medical University, Shijiazhuang, P. R. China.; Research Centre, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P. R. China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2022 Oct 04; Vol. 17 (10), pp. e0273163. Date of Electronic Publication: 2022 Oct 04 (Print Publication: 2022).
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Melanoma*
Skin Neoplasms*
B7-H1 Antigen ; Biomarkers, Tumor/metabolism ; CTLA-4 Antigen ; Humans ; Prognosis ; Programmed Cell Death 1 Receptor ; RNA, Messenger/genetics ; RNA-Binding Proteins ; Tumor Microenvironment/genetics ; Ubiquitins ; Melanoma, Cutaneous Malignant

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Autorzy:: Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.
Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: CTLA-4 Antigen/*immunology
HIV Infections/*drug therapy
HIV-1/*immunology
Ipilimumab/*administration & dosage
Viremia/*drug therapy
Adult ; CD4 Lymphocyte Count ; CTLA-4 Antigen/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; RNA, Viral/blood ; Viremia/immunology ; Viremia/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Autorzy:: Arnoletti JP; Center for Surgical Oncology, AdventHealth Cancer Institute, Orlando, Florida, United States of America.
Reza J; General SurgeryResidency Program, AdventHealth, Orlando, Florida, United States of America.
Rosales A; Center for Surgical Oncology, AdventHealth Cancer Institute, Orlando, Florida, United States of America.
Monreal A; General SurgeryResidency Program, AdventHealth, Orlando, Florida, United States of America.
Fanaian N; Central Florida Pathology Associates, Orlando, Florida, United States of America.
Whisner S; AdventHealth Research Institute, Orlando, Florida, United States of America.
Srivastava M; AdventHealth Research Institute, Orlando, Florida, United States of America.
Rivera-Otero J; AdventHealth Research Institute, Orlando, Florida, United States of America.
Yu G; AdventHealth Research Institute, Orlando, Florida, United States of America.
Phanstiel Iv O; Department of Medical Education, College of Medicine, University of Central Florida, Orlando, Florida, United States of America.
Altomare DA; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, United States of America.
Tran Q; Translational Research, AdventHealth Cancer Institute, Winter Park, Florida, United States of America.
Litherland SA; Translational Research, AdventHealth Cancer Institute, Winter Park, Florida, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2022 Mar 22; Vol. 17 (3), pp. e0265725. Date of Electronic Publication: 2022 Mar 22 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Pancreatic Ductal*/pathology
Neoplastic Cells, Circulating*
Pancreatic Neoplasms*/pathology
Animals ; CTLA-4 Antigen ; Cell Differentiation ; Culture Media, Conditioned ; Humans ; Interleukin-8/genetics ; Macrophage Colony-Stimulating Factor/metabolism ; Portal Vein/pathology ; RNA ; Rabbits ; Tumor Microenvironment ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Autorzy:: Kassardjian A; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Shintaku PI; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Moatamed NA; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2018 Apr 19; Vol. 13 (4), pp. e0195958. Date of Electronic Publication: 2018 Apr 19 (Print Publication: 2018).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor*
B7-H1 Antigen/*genetics
Breast Neoplasms/*genetics
CTLA-4 Antigen/*genetics
T-Lymphocyte Subsets/*metabolism
Adult ; B7-H1 Antigen/metabolism ; Breast Neoplasms/immunology ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; CTLA-4 Antigen/metabolism ; Carcinoma, Intraductal, Noninfiltrating/genetics ; Carcinoma, Intraductal, Noninfiltrating/immunology ; Carcinoma, Intraductal, Noninfiltrating/metabolism ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Carcinoma, Lobular/metabolism ; Carcinoma, Lobular/pathology ; Female ; Gene Expression ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; T-Lymphocyte Subsets/immunology ; Tissue Array Analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Autorzy:: Gombos RB; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Gonzalez A; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Manrique M; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Chand D; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Savitsky D; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Morin B; Research Biochemistry, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Breous-Nystrom E; Agenus Switzerland Incorporated, Basel, Switzerland.
Dupont C; Translational Biomarkers, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Ward RA; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Mundt C; Agenus Switzerland Incorporated, Basel, Switzerland.
Duckless B; Translational Biomarkers, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Tang H; Translational Biomarkers, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Findeis MA; Research Biochemistry, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Schuster A; Agenus Switzerland Incorporated, Basel, Switzerland.
Waight JD; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Underwood D; Research Biochemistry, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Clarke C; Safety, Pharmacology and Toxicology, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Ritter G; The Ludwig Institute for Cancer Research, New York, New York, United States of America.
Merghoub T; Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Schaer D; Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Wolchok JD; Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
van Dijk M; Agenus United Kingdom Limited, Cambridge, United Kingdom.
Buell JS; Research and Development Management, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Cuillerot JM; Research and Development Management, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Stein R; Research and Development Consultant, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Drouin EE; Translational Biomarkers, Agenus Incorporated, Lexington, Massachusetts, United States of America.
Wilson NS; Immuno-modulatory Drug Discovery, Agenus Incorporated, Lexington, Massachusetts, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2018 Apr 04; Vol. 13 (4), pp. e0191926. Date of Electronic Publication: 2018 Apr 04 (Print Publication: 2018).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adjuvants, Immunologic/*pharmacology
Antineoplastic Agents, Immunological/*pharmacology
CTLA-4 Antigen/*immunology
Immunoglobulin G/*pharmacology
Neoplasms/*therapy
Adjuvants, Immunologic/chemistry ; Adjuvants, Immunologic/pharmacokinetics ; Adjuvants, Immunologic/toxicity ; Amino Acid Sequence ; Animals ; Antibody Formation/drug effects ; Antineoplastic Agents, Immunological/chemistry ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Agents, Immunological/toxicity ; CHO Cells ; CTLA-4 Antigen/antagonists & inhibitors ; Cancer Vaccines/pharmacology ; Cells, Cultured ; Cricetulus ; Epitope Mapping ; Humans ; Immunity, Cellular/drug effects ; Immunoglobulin G/chemistry ; Immunoglobulin G/toxicity ; Lymphocyte Activation/drug effects ; Macaca fascicularis ; Models, Molecular ; Neoplasms/immunology ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/immunology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Effect of PTPN22, FAS/FASL, IL2RA and CTLA4 genetic polymorphisms on the risk of developing alopecia areata: A systematic review of the literature and meta-analysis.
Autorzy:: Gil-Quiñones SR; Clinical Epidemiology Program, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Sepúlveda-Pachón IT; Clinical Epidemiology Program, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Sánchez Vanegas G; Clinical Epidemiology Program, Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Gutierrez-Castañeda LD; Research Institute, Group of Basic Sciences in Health (CBS)-FUCS, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Nov 04; Vol. 16 (11), pp. e0258499. Date of Electronic Publication: 2021 Nov 04 (Print Publication: 2021).
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:: Alopecia Areata/*genetics
CTLA-4 Antigen/*genetics
Fas Ligand Protein/*genetics
Interleukin-2 Receptor alpha Subunit/*genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 22/*genetics
fas Receptor/*genetics
Alleles ; Alopecia Areata/epidemiology ; Alopecia Areata/pathology ; Genetic Association Studies ; Genetic Predisposition to Disease ; Genotype ; Humans ; Polymorphism, Single Nucleotide/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Autorzy:: Linedale R; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.
Schmidt C; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.; Department of Otolaryngology-Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia.; The University of Queensland Faculty of Medicine, Brisbane, Australia.
King BT; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.; The University of Queensland Faculty of Medicine, Brisbane, Australia.
Ganko AG; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.; The University of Queensland Faculty of Medicine, Brisbane, Australia.
Simpson F; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.
Panizza BJ; Department of Otolaryngology-Head and Neck Surgery, Princess Alexandra Hospital, Brisbane, Australia.; The University of Queensland Faculty of Medicine, Brisbane, Australia.
Leggatt GR; The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Apr 19; Vol. 12 (4), pp. e0175755. Date of Electronic Publication: 2017 Apr 19 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: CTLA-4 Antigen/*genetics
Carcinoma, Squamous Cell/*genetics
Head and Neck Neoplasms/*genetics
Hepatitis A Virus Cellular Receptor 2/*genetics
Neoplasm Recurrence, Local/*genetics
Programmed Cell Death 1 Receptor/*genetics
Skin Neoplasms/*genetics
Aged ; Aged, 80 and over ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/pathology ; CTLA-4 Antigen/immunology ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/surgery ; Cohort Studies ; Cranial Nerves/immunology ; Cranial Nerves/pathology ; Cranial Nerves/surgery ; Female ; Flow Cytometry ; Gene Expression Regulation, Neoplastic ; Head and Neck Neoplasms/immunology ; Head and Neck Neoplasms/pathology ; Head and Neck Neoplasms/surgery ; Hepatitis A Virus Cellular Receptor 2/immunology ; Humans ; Killer Cells, Natural/immunology ; Killer Cells, Natural/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/surgery ; Programmed Cell Death 1 Receptor/immunology ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Skin Neoplasms/surgery

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.
Autorzy:: Young KH; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.; The Oregon Clinic, Portland, OR, 97213, United States of America.
Baird JR; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Savage T; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Cottam B; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Friedman D; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Bambina S; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Messenheimer DJ; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Fox B; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Newell P; The Oregon Clinic, Portland, OR, 97213, United States of America.; Providence Hepatobiliary and Pancreatic Cancer Program, Providence Portland Medical Center, 4805, NE Glisan St, Portland, OR, 97213, United States of America.
Bahjat KS; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Gough MJ; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.
Crittenden MR; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR, 97213, United States of America.; The Oregon Clinic, Portland, OR, 97213, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Jun 09; Vol. 11 (6), pp. e0157164. Date of Electronic Publication: 2016 Jun 09 (Print Publication: 2016).
Typ publikacji:: Journal Article
MeSH Terms:: Immunotherapy*
CD8-Positive T-Lymphocytes/*immunology
CTLA-4 Antigen/*immunology
Colorectal Neoplasms/*therapy
Mammary Neoplasms, Animal/*therapy
Receptors, OX40/*immunology
T-Lymphocytes, Regulatory/*immunology
Animals ; Antigen Presentation ; CTLA-4 Antigen/metabolism ; Colorectal Neoplasms/immunology ; Combined Modality Therapy ; Dose Fractionation, Radiation ; Female ; Mammary Neoplasms, Animal/immunology ; Mice ; Mice, Inbred BALB C ; Time Factors ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: A novel mouse model for checkpoint inhibitor-induced adverse events.
Autorzy:: Adam K; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, United States of America.
Iuga A; Department of Pathology, Columbia University Medical Center, New York, New York, United States of America.
Tocheva AS; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, United States of America.
Mor A; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Feb 11; Vol. 16 (2), pp. e0246168. Date of Electronic Publication: 2021 Feb 11 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Immune Checkpoint Inhibitors/*adverse effects
Animals ; Anti-Inflammatory Agents/pharmacology ; Antibodies, Monoclonal/immunology ; CTLA-4 Antigen/immunology ; Disease Models, Animal ; Genetic Variation ; Leukocytes/drug effects ; Leukocytes/immunology ; Mice ; Organ Specificity ; Programmed Cell Death 1 Receptor/immunology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) Gene Polymorphisms with Autoimmune Thyroid Disease in Children and Adults: Case-Control Study.
Autorzy:: Ting WH; Department of Pediatrics, MacKay Children's Hospital, Taipei, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.; MacKay Junior College of Medicine, Nursing and Management, New Taipei City, Taiwan.
Chien MN; Department of Endocrinology and Metabolism, MacKay Memorial Hospital, Taipei, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.; Institute of Mechatronic Engineering, National Taipei University of Technology, Taipei, Taiwan.; MacKay Junior College of Medicine, Nursing and Management, New Taipei City, Taiwan.
Lo FS; Department of Pediatrics, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan.; College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
Wang CH; Department of Endocrinology and Metabolism, MacKay Memorial Hospital, Taipei, Taiwan.
Huang CY; Department of Pediatrics, MacKay Children's Hospital, Taipei, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
Lin CL; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Lin WS; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Chang TY; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Yang HW; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Chen WF; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Lien YP; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.
Cheng BW; Department of Pediatrics, MacKay Memorial Hospital HsinChu, Hsin-Chu, Taiwan.
Lin CH; Department of Pediatrics, MacKay Memorial Hospital HsinChu, Hsin-Chu, Taiwan.
Chen CC; Department of Pediatrics, Chiayi Christian Hospital, Chia-Yi, Taiwan.
Wu YL; Department of Pediatrics, Changhua Christian Hospital, Chang-Hua, Taiwan.
Hung CM; Department of Pediatrics, Hsinchu Cathay General Hospital, Hsin-Chu, Taiwan.
Li HJ; Department of Pediatrics, St. Martin De Porres Hospital, Chia-Yi, Taiwan.
Chan CI; Department of Pediatrics, MacKay Children's Hospital, Taipei, Taiwan.
Lee YJ; Department of Pediatrics, MacKay Children's Hospital, Taipei, Taiwan.; Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.; Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan.; Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, Taiwan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Apr 25; Vol. 11 (4), pp. e0154394. Date of Electronic Publication: 2016 Apr 25 (Print Publication: 2016).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Genetic Predisposition to Disease*
Polymorphism, Single Nucleotide*
CTLA-4 Antigen/*genetics
Graves Disease/*genetics
Hashimoto Disease/*genetics
Adolescent ; Adult ; Aged ; Alleles ; Asian People ; CTLA-4 Antigen/immunology ; Case-Control Studies ; Child ; Child, Preschool ; Female ; Gene Expression ; Gene Frequency ; Graves Disease/ethnology ; Graves Disease/immunology ; Graves Disease/pathology ; Haplotypes ; Hashimoto Disease/ethnology ; Hashimoto Disease/immunology ; Hashimoto Disease/pathology ; Heterozygote ; Humans ; Linkage Disequilibrium ; Male ; Middle Aged ; Odds Ratio ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Cytotoxic/pathology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Association of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Thyroglobulin (TG) Genetic Variants with Autoimmune Hypothyroidism.
Autorzy:: Patel H; Pharmacy Department, Faculty of Technology & Engineering, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Mansuri MS; Biochemistry Department, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Singh M; Biochemistry Department, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Begum R; Biochemistry Department, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Shastri M; Medicine Department, Faculty of Medicine, Sir Sayajirao Gaekwad Hospital, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.
Misra A; Pharmacy Department, Faculty of Technology & Engineering, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Mar 10; Vol. 11 (3), pp. e0149441. Date of Electronic Publication: 2016 Mar 10 (Print Publication: 2016).
Typ publikacji:: Journal Article
MeSH Terms:: Genetic Association Studies*
Genetic Predisposition to Disease*
CTLA-4 Antigen/*genetics
Hashimoto Disease/*genetics
Polymorphism, Single Nucleotide/*genetics
Thyroglobulin/*genetics
Thyroiditis, Autoimmune/*genetics
3' Untranslated Regions/genetics ; CTLA-4 Antigen/metabolism ; Case-Control Studies ; Exons/genetics ; Female ; Gene Expression Regulation ; Haplotypes/genetics ; Humans ; Iodide Peroxidase/immunology ; Linkage Disequilibrium/genetics ; Logistic Models ; Male ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Thyroglobulin/metabolism
SCR Disease Name:: Hypothyroidism, Autoimmune

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Autorzy:: Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Cheng PF; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Schindler K; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Weide B; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Held U; Horten Centre for Patient Oriented Research and Knowledge Transfer, University Hospital Zurich, Zurich, Switzerland.
Frauchiger AL; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Romano E; Department of Oncology CHUV Lausanne, Lausanne, Switzerland.
Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
Rozati S; Department of Dermatology, Stanford University School of Medicine, Stanford, United States of America.
Rechsteiner M; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
Moch H; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
Michielin O; Department of Oncology CHUV Lausanne, Lausanne, Switzerland.
Garbe C; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Hauschild A; Department of Dermatology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
Hoeller C; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Goldinger SM; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Oct 01; Vol. 10 (10), pp. e0139438. Date of Electronic Publication: 2015 Oct 01 (Print Publication: 2015).
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
CTLA-4 Antigen/*antagonists & inhibitors
GTP Phosphohydrolases/*genetics
Melanoma/*genetics
Melanoma/*mortality
Membrane Proteins/*genetics
Mutation/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Biomarkers, Tumor/genetics ; CTLA-4 Antigen/immunology ; Female ; Follow-Up Studies ; Genotype ; Humans ; Male ; Melanoma/drug therapy ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.
Autorzy:: Jeffery LE; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom.
Qureshi OS; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom.
Gardner D; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom.
Hou TZ; UCL Institute of Immunity and Transplantation, Royal Free Campus, University College London, London, United Kingdom.
Briggs Z; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom.
Soskic B; UCL Institute of Immunity and Transplantation, Royal Free Campus, University College London, London, United Kingdom.
Baker J; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom.
Raza K; Medical Research Council Centre for Immune Regulation, School of Immunity and Infection, Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, United Kingdom; Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom.
Sansom DM; UCL Institute of Immunity and Transplantation, Royal Free Campus, University College London, London, United Kingdom.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Jul 02; Vol. 10 (7), pp. e0131539. Date of Electronic Publication: 2015 Jul 02 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: CTLA-4 Antigen/*metabolism
Cytokines/*metabolism
Inflammation/*metabolism
Vitamin D/*metabolism
Animals ; Antigen-Presenting Cells/cytology ; B7-1 Antigen/metabolism ; B7-2 Antigen/metabolism ; CHO Cells ; CTLA-4 Antigen/genetics ; Calcitriol/metabolism ; Cricetinae ; Cricetulus ; Endocytosis ; Gene Expression Regulation ; Humans ; Leukocytes, Mononuclear/metabolism ; Lymphocyte Activation/immunology ; Real-Time Polymerase Chain Reaction ; Receptors, Calcitriol/metabolism ; T-Lymphocytes, Regulatory/cytology ; Th17 Cells/cytology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
Autorzy:: Condomines M; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.
Arnason J; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.
Benjamin R; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.
Gunset G; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.
Plotkin J; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.
Sadelain M; Center for Cell Engineering and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Jun 25; Vol. 10 (6), pp. e0130518. Date of Electronic Publication: 2015 Jun 25 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Immunotherapy, Adoptive*
CTLA-4 Antigen/*immunology
Neoplasms/*immunology
Animals ; Antigens, CD19/immunology ; CD28 Antigens/administration & dosage ; CD28 Antigens/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; Gene Expression Regulation/immunology ; Humans ; Lymphocyte Activation/immunology ; Mice ; Neoplasms/pathology ; Neoplasms/therapy ; Receptors, Antigen/administration & dosage ; Receptors, Antigen/immunology ; T-Lymphocytes/immunology ; Xenograft Model Antitumor Assays

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Autorzy:: Higashikawa K; Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan; Japan Society for the Promotion of Science, Tokyo, Japan.
Yagi K; Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Watanabe K; Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Kamino S; Next-generation Imaging Team, RIKEN Center for Life Science Technologies, Kobe, Japan.
Ueda M; Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Hiromura M; Next-generation Imaging Team, RIKEN Center for Life Science Technologies, Kobe, Japan.
Enomoto S; Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan; Next-generation Imaging Team, RIKEN Center for Life Science Technologies, Kobe, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2014 Nov 03; Vol. 9 (11), pp. e109866. Date of Electronic Publication: 2014 Nov 03 (Print Publication: 2014).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal*
Copper Radioisotopes*
Organometallic Compounds*
Positron-Emission Tomography*/methods
CTLA-4 Antigen/*metabolism
Lymphocytes, Tumor-Infiltrating/*metabolism
Neoplasms/*diagnosis
Neoplasms/*metabolism
Animals ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; Cell Line, Tumor ; Disease Models, Animal ; Female ; Gene Expression ; Humans ; Mice ; Neoplasms/genetics ; Protein Binding ; Radiopharmaceuticals

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""CTLA-4"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Język